Price Alert

Akero Therapeutics Inc. (AKRO)

NASDAQ: AKRO · Real-Time Price · USD

53.66

0.06 (0.11%)

At close: Oct 16, 2025, 3:59 PM

53.66

0.00%

After-hours: Oct 16, 2025, 07:59 PM EDT

0.11% (1D)

Bid	53.52
Market Cap	4.29B
Revenue (ttm)	4K
Net Income (ttm)	-283.96M
EPS (ttm)	-3.81
PE Ratio (ttm)	-14.08
Forward PE	-12.66
Analyst	Buy
Dividends	n/a

Ask	53.8
Volume	2,213,910
Avg. Volume (20D)	1,903,103
Open	53.73
Previous Close	53.60
Day's Range	53.60 - 53.87
52-Week Range	21.34 - 58.40
Beta	-0.29
Ex-Dividend Date	n/a

About AKRO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AKRO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AKRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 week ago

+16.33%

Akero Therapeutics shares are trading higher after... Unlock content with Pro Subscription

8 months ago

+97.52%

Akero Therapeutics shares are trading higher after the company reported preliminary Week 96 results from its SYMMETRY Phase 2B study of Efruxifermin.

News

6 days ago · businesswire.com

Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akero...

6 days ago · invezz.com

Akero Therapeutics soars after Novo Nordisk set for $5.2B cash acquisition

Novo Nordisk said on Thursday it would acquire Akero Therapeutics for up to $5.2 billion in cash, marking a significant push into treatments for fatty liver disease as the Danish drugmaker seeks to br...

6 days ago · seekingalpha.com

Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX

Akero Therapeutics is being acquired by Novo Nordisk for up to $5.2 billion, driven by strong phase 2b results for EFX in F2/F3 pre-cirrhotic and compensated cirrhosis F4 MASH patients. Akero's EFX sh...

1 week ago · investopedia.com

Top Stock Movers Now: Delta Air Lines, PepsiCo, Akero Therapeutics, and More

Major U.S. equities indexes pulled back Thursday after the S&P 500 and Nasdaq set fresh all-time highs. The Dow Jones Industrial Average, S&P 500, and Nasdaq all were lower at midday.

1 week ago · fastcompany.com

Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug

Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's ...

1 week ago · schaeffersresearch.com

Akero Therapeutics Stock Surges on Novo Nordisk Buyout

Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc (NA...

1 week ago · benzinga.com

Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion

Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.

1 week ago · proactiveinvestors.com

Novo Nordisk acquires Akero Therapeutics and its promising liver therapy for up to $5.2B

Novo Nordisk (NYSE:NVO) announced it is acquiring Akero Therapeutics (NASDAQ: AKRO) for a total potential value of up to $5.2 billion, strengthening its pipeline in treatments for metabolic dysfunctio...

1 week ago · businesswire.com

AKRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akero Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akero Therapeutics, Inc. (NASDAQ: AKRO) to Novo Nordisk A/S is fair to Akero shareholders...

1 week ago · barrons.com

Akero Therapeutics Stock Soars on Novo Nordisk Deal.

Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of Efruxifermin - it's treatment for fatty liver disease.

Load More News